Parallel Advisors’s Traws Pharma TRAW Stock Holding History

Parallel Advisors’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1	Closed	–	–	3537
2022 Q3	$0	Hold	1	–	–	﹤0.01%	3542
2022 Q2	$0	Hold	1	–	–	﹤0.01%	3406
2022 Q1	$0	Hold	1	–	–	﹤0.01%	3315
2021 Q4	$0	Hold	1	–	–	﹤0.01%	3323
2021 Q3	$0	Buy	+1	New	+$129	﹤0.01%	3299

Other funds holding TRAW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Parallel Advisors's TRAW Position: Q4 2022 in Review

Parallel Advisors sold out of Traws Pharma (TRAW) in Q4 2022, closing a stake of 1 share.

Parallel Advisors first reported a position in TRAW in Q3 2021 and held it in 5 quarters. The position peaked at $0 in Q3 2022. 28 funds tracked by Wall St. Rank hold TRAW as of Q4 2022.

Parallel Advisors reported no remaining Traws Pharma position as of Q4 2022 after selling out during the quarter.
Parallel Advisors sold 1 Traws Pharma share in Q4 2022.
Parallel Advisors first reported a position in Traws Pharma in Q3 2021 and held it in 5 quarters.
Parallel Advisors's Traws Pharma position peaked at $0 in Q3 2022.
28 funds tracked by Wall St. Rank held Traws Pharma as of Q4 2022.

Based on Parallel Advisors's 13F filing for Q4 2022, filed 6 Feb 2023.